Brokerages Set Sanofi (NASDAQ:SNY) PT at $57.50

Shares of Sanofi (NASDAQ:SNY) have been assigned an average rating of “Moderate Buy” from the four research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $57.50.

Several research firms recently issued reports on SNY. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th.

Sanofi Price Performance

Shares of SNY stock opened at $48.49 on Thursday. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm’s 50 day moving average is $52.80 and its 200-day moving average is $52.13. The firm has a market capitalization of $123.06 billion, a price-to-earnings ratio of 24.74, a PEG ratio of 1.23 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.55 EPS. Sell-side analysts forecast that Sanofi will post 4.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Sanofi

Several hedge funds have recently bought and sold shares of SNY. Franklin Resources Inc. lifted its holdings in shares of Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after purchasing an additional 395,744 shares in the last quarter. Tidal Investments LLC increased its position in shares of Sanofi by 126.7% during the third quarter. Tidal Investments LLC now owns 13,798 shares of the company’s stock worth $795,000 after acquiring an additional 7,711 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Sanofi during the third quarter worth $219,000. World Investment Advisors LLC lifted its position in Sanofi by 1,020.5% in the 3rd quarter. World Investment Advisors LLC now owns 48,430 shares of the company’s stock valued at $2,791,000 after acquiring an additional 44,108 shares in the last quarter. Finally, Sanctuary Advisors LLC boosted its stake in Sanofi by 8.5% in the 3rd quarter. Sanctuary Advisors LLC now owns 96,135 shares of the company’s stock worth $5,540,000 after purchasing an additional 7,556 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.